Similarly administration of Ascorbate and Trolox as a combination (A+T) at reperfusion significantly decreased hypertonia to 20.0% in surviving kits compared to 59.4% in saline control group.
When MnTnHex-2-PyP was administered at onset of reperfusion (post-treatment), there was no protection.